<DOC>
	<DOCNO>NCT01095835</DOCNO>
	<brief_summary>This study compare efficacy safety 2 different duration treatment pegylated interferon ( PEG-IFN ) alfa-2a participant Hepatitis B e Antigen ( HBeAg ) -negative chronic hepatitis B virus ( HBV ) . It also compare PEG-IFN alfa 2a treatment alone combination lamivudine ( LAM ) . The anticipated time study treatment 1-2 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Pegylated Interferon Alfa-2a Lamivudine Patients With HBeAg-Negative Chronic Hepatitis B Virus ( HBV )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>adult 1870 year age ; HBeAgnegative chronic hepatitis B &gt; /=6 month ; liver disease consistent chronic hepatitis B. interferonbased , systemic antiHBV , antiviral , antineoplastic , immunomodulatory therapy &lt; /=12 month first dose study drug ; nonresponders previous interferon therapy ; coinfection hepatitis A , C D , human immunodeficiency virus ( HIV ) ; hepatocellular cancer ; compensate ( Child A , score 6 ) decompensated liver disease ( Child B C ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>